Pancreatic Cancer Research

ResearcherAlligator Bioscience (Sweden)Active in the last 2 years

Yago Pico de Coaña

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5362-8761; OpenAlex author ID A5014107242. Sources: ClinicalTrials.gov.

Their work

Papers
2
Trials
1
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2021: 1 trial · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 2

  1. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  2. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗

Trials 1

  1. Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients Study director NCT04888312↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Luc Van Laethem · 2 shared papers, 1 shared trial, 2021–2025 · strength 0.78
  2. Emmanuel Mitry · 2 shared papers, 2024–2025 · strength 0.36
  3. Jean‐Frédéric Blanc · 2 shared papers, 2024–2025 · strength 0.36
  4. Hans Prenen · 2 shared papers, 2024–2025 · strength 0.36
  5. Karen Paula Geboes · 2 shared papers, 2024–2025 · strength 0.36
  6. Lorenzo Pilla · 2 shared papers, 2024–2025 · strength 0.36
  7. Roberto Pazo-Cid · 2 shared papers, 2024–2025 · strength 0.36
  8. Aurélien Lambert · 2 shared papers, 2024–2025 · strength 0.36
  9. Jaime Feliú · 2 shared papers, 2024–2025 · strength 0.36
  10. Philippe Alexandre Cassier · 2 shared papers, 2024–2025 · strength 0.36
  11. Teresa Mercade Macarulla · 2 shared papers, 2024–2025 · strength 0.36
  12. Eileen Mary O'Reilly · 1 shared paper, 2025 · strength 0.19
  13. Gregory Lawrence Beatty · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.